Kiora Pharmaceuticals, Inc.
KPRX · Nasdaq · United States
Share price · KPRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KPRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-11.3%
Nothing announced by KPRX that day or the session before.
- 16 Nov 2026-20.2%
- Day beforeEarnings date (period ending 2026-09-30)
- 30 Oct 2026-11.4%
- 29 Oct 2026-25.4%
- 25 Aug 2026-5.8%
Nothing announced by KPRX that day or the session before.
- 9 Apr 2026-13.3%
Nothing announced by KPRX that day or the session before.
- 8 Apr 2026+32.4%
- 7 Apr 2026+6.9%
- 9 Mar 2026+8.1%
Nothing announced by KPRX that day or the session before.
- 29 Jan 2026+7.5%
Nothing announced by KPRX that day or the session before.
Share of unusual movement by asset
For each asset, the share of KPRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
KIO-301events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 38% |
| Sessions with no dated event | — | 62% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Retinal ion channels (light-gated photoswitch)Small molecule | Retinitis Pigmentosa |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.0M | $1.9M | $5.6M+ $11M short-term inv. | $1.8M-$0.6M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $2.1M | $7.1M+ $9.8M short-term inv. | $2.1M-$1.9M operating cash flow | report ↗ |
| 2026-Q1 | — | $2.1M | $11M+ $2.9M short-term inv. | $2.4M-$3.2M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $2.7M | $5.5M+ $14M short-term inv. | —-$1.3M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $2.6M | $1.0M+ $20M short-term inv. | $2.1M-$3.8M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $2.5M | $3.8M+ $20M short-term inv. | $2.2M-$2.7M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $1.3M | $5.6M+ $23M short-term inv. | $3.4M$0.9M operating cash flow | report ↗ |
| 2024-Q2 | <$0.1M | $0.9M | $6.6M+ $21M short-term inv. | $2.2M-$3.7M operating cash flow | report ↗ |
| 2024-Q1 | $16M | $1.5M | $31M | —$14M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $1.1M | $5.4M | $5.8M-$2.5M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $1.4M | $8.0M | $2.6M-$1.4M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $0.4M | $3.4M | $1.9M-$3.1M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.3M | $4.8M | $5.1M-$3.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $0.6M | $2.5M | $2.4M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $0.7M | $5.1M | $3.6M-$2.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.6M | $11M | $3.0M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $11M | $8.7M+ $8.4M short-term inv. | $2.7M-$10.0M operating cash flow | report ↗ |
For fiscal 2025, Kiora Pharmaceuticals reported revenue of $0M, down 100.0% YoY from $16.02M in 2024, which had reflected a $16.0M upfront collaboration payment from Laboratoires Théa. R&D expense was $10.78M, up 37.5% YoY. The company ended 2025 with $17.1M in cash, cash equivalents, and short-term investments (including $8.7M of cash and equivalents) and posted a net loss of $10.84M versus net income of $3.6M in 2024; net cash used in operating activities was $2.2M in Q4 and $10.0M for the full year.
Management guided that existing cash, cash equivalents, and short-term investments should fund operations into late 2027, beyond anticipated topline data readouts for the ABACUS-2 and KLARITY trials. The company advanced KIO-301 to patient dosing in the Phase 2 ABACUS-2 trial for advanced retinitis pigmentosa, with an initial data readout anticipated in Q3 2027, and entered an option agreement with Senju Pharmaceutical covering key Asian markets for a potential deal value of up to $110M plus royalties. KIO-104 was advanced to patient dosing in the Phase 2 KLARITY trial for macular edema due to retinal inflammation, and KIO-300 demonstrated preclinical ex vivo proof of concept as an ion-channel modulator in epilepsy.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $16M | $7.8M | $3.8M+ $23M short-term inv. | —$8.6M operating cash flow | report ↗ |
| 2023-FY | $0 | $4.0M | $2.5M+ $0 short-term inv. | $3.1M-$9.6M operating cash flow | report ↗ |
| 2022-FY | — | $3.5M | $6.0M | $3.4M-$10M operating cash flow | report ↗ |
| 2021-FY | — | $5.3M | $7.9M | $4.1M-$11M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-17 | Lane Keith J. · EVP, Clinical and Regulatory | Award / grant (derivative) | 55,000 | — | — | Form 4 |
| 2026-07-01 | Strem Brian M. · director, President and CEO | Tax withholding | 1,869 | $2.66 | $5K | Form 4 |
| 2026-07-01 | Tosca Melissa · CFO | Tax withholding | 911 | $2.66 | $2K | Form 4 |
| 2026-06-10 | TYLE PRAVEEN · director | Award / grant (derivative) | 40,000 | — | — | Form 4 |
| 2026-06-10 | Walters-Hoffert Lisa · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-06-10 | Hollander David · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-06-10 | Parsons Erin · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |
| 2026-06-10 | Shapiro Aron · director | Award / grant (derivative) | 25,000 | — | — | Form 4 |